AI/ML in Antibody Discovery: What Works, What Doesn’t, What’s Next
Traditional antibody discovery is a war of attrition: screen thousands of candidates, fail late, and repeat. AI/ML changes that calculus by shifting failures from late and expensive to early and cheap. The result is fewer wet-lab cycles and a higher probability that the molecules you carry forward actually behave like drugs, while at the same time integrating learnings from failures at every stage.
From Data to Decisions in Antibody Discovery: Integrating AI/ML
WEBINAR Register for our upcoming webinar on integrating AI/ML workflows to drive smarter antibody selection, developability triage, and lead optimization. Tue, Mar. 31 | 11:00 AM EST Register Now Webinar Overview: AI/ML is reshaping antibody discovery, not by replacing the lab, but by making every wet-lab cycle smarter. In this webinar, Alloy will share practical, […]
Alloy Accelerates Mediar Timeline to the Clinic for Complex Fibrosis Targets
Antibody discovery for complex fibrosis targets requires advanced platforms capable of addressing difficult biology. Alloy Therapeutics partnered with Mediar to accelerate high-quality antibody programs into IND-enabling studies.
Accelerated Antibody Discovery for Complex Fibrosis Targets
Accelerating Antibody Discovery for Challenging Fibrosis Targets Download Case Study Contact Us Advancing a first-in-class fibrosis program against complex biology This case study highlights how Alloy’s antibody discovery platforms and execution model enabled Mediar Therapeutics to move a complex fibrosis program forward with speed and confidence, despite biological and technical barriers that stalled conventional discovery […]
Tahoe Therapeutics and Alloy Therapeutics to Form Joint Venture and Develop First-in-Class Antibody-Drug Conjugates for Hard-to-Treat Cancers
The new company combines Tahoe’s AI-powered target discovery engine with Alloy’s industry-leading ADC development capabilities to advance two first-in-class oncology programs built on deeply validated tumor targets.
Swiss Rockets Group and Alloy Therapeutics Partner to Advance Radioligand Therapeutics in Oncology
Collaboration combines Alloy’s antibody discovery and engineering platforms with Torpedo’s radiopharmaceutical development capabilities – including Terbium-161 – to advance next-generation oncology RLT candidates toward clinical development
Leveraging Human Lambda Light Chains in Antibody Discovery
Harnessing the potential of human lambda light chains in antibody discovery Download White Paper Contact Us Expanding antibody discovery potential with human lambda light chains Despite the kappa/lambda ratio in human circulation being between 1.5 and 2, therapeutic antibodies remain heavily biased toward kappa light chain usage. Our white paper explores how Alloy’s ATX-GL platform […]
De-risking antibody discovery through comprehensive developability profiling
De-risking antibody discovery through comprehensive developability profiling Download Tech Note Contact Us Select leads with confidence by integrating biophysical assays, computational analysis, and clinical benchmarking from the earliest stages of discovery. Despite strong target binding, many therapeutic antibodies fail late in development due to preventable issues related to stability, manufacturability, or pharmacokinetics. Alloy’s integrated developability […]
Webinar: Unlocking Smarter Antibody Selection Strategies
Download our webinar on unlocking smarter antibody selection strategies to improve clinical success potential through integrated in vitro and in silico developability assessments. Watch now Webinar Overview: Many promising antibody therapeutics fail in development due to poor biophysical properties that can impact PK, stability, and manufacturability. This webinar presents an integrated strategy for early-stage developability […]
Alloy Therapeutics Announces Acquisition of Spannerwerks, a Leading Provider of Drug Development Consulting Services
BOSTON — October 23, 2025 — Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting-edge drug discovery technologies, today announced the acquisition of Spannerwerks, LLC, a Seattle-based professional services firm that guides biopharmaceuticals on the development and launch of new products. Under the terms of the agreement, Spannerwerks will operate […]